Avisio signs agreement to commercialize Instant Detect diagnostic technology

Avisio, Inc. (PINKSHEETS: AVIC) announces the signing of a definitive agreement to commercialize Instant Detect, a portable nano-based diagnostic technology. Avisio, a publicly-traded commercialization company with a mission to unlock the value of high-potential assets and transform them into high-value businesses, now has the worldwide license to commercialize Instant Detect's ground-breaking portable diagnostic sensory technology. With the agreement, Avisio has exclusive acquisition rights for 18 months.

Instant Detect's sensory technology will be incorporated into a highly sensitive handheld instrument designed for use in the field. Using nanosensors, the technology allows for the testing of viruses, bacteria and other disease-causing pathogens in a non-laboratory environment, with immediately available results that do not require the expertise of a specialized lab technician to read.

Among potential uses envisioned for the technology, professional individuals will ultimately be able to instantly detect such disease-causing pathogens as H1N1, West Nile Virus, dengue, malaria and encephalitis among at risk populations, while agricultural inspectors will be able to detect pathogens in the food supply and farmers will be able to detect plant diseases and livestock pathogens instantly. The device will require no specialized training and can detect pathogens from a broad range of samples.

Avisio intends to make the product commercially available in the second half of 2010.

SOURCE: Avisio, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cognitive behavioral therapy shows promise for prolonged grief disorder